Abstract
Lapatinib, an oral dual ErbB1/2 tyrosine kinase inhibitor, is effective in the treatment of metastatic breast cancer that has progressed after trastuzumab-based first-line chemotherapy. Moreover, lapatinib has been found to be effective in patients with metastatic brain involvement. Here we report the case of a 55-year-old woman with metastatic breast cancer and brain metastasis who achieved rapid symptom improvement and long-term disease control.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / metabolism
-
Brain Neoplasms / secondary*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology*
-
Breast Neoplasms / radiotherapy
-
Female
-
Humans
-
Lapatinib
-
Middle Aged
-
Neoplasm Staging
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Quinazolines / therapeutic use*
-
Radiotherapy, Adjuvant
-
Receptor, ErbB-2 / antagonists & inhibitors*
-
Time Factors
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Lapatinib
-
ERBB2 protein, human
-
Protein-Tyrosine Kinases
-
Receptor, ErbB-2